A phase I open label dose escalation and dose-expansion study to evaluate the safety toloerability pharmcokinetics immunogenicity and antitumor activate of Medi-9447 alone and in combination with MEDI

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2015 - September 30, 2021